Even though some naturally occurring compounds that inhibit NF-κB signaling pathways (particularly IKK inhibitors) are available, but more specific inhibitors of IKK and other upstream kinases need to be further studied clinically to confirm their potential in patients with GBM. The gene discussed is NFKB1; the disease is glioblastoma.